Navigation Links
Cynvenio Announces New LiquidBiopsy® Test for PD-L2 Expression
Date:9/6/2017

Cynvenio Biosystems, Inc., a leader in liquid biopsy testing technology for personalized medicine, today announced the launch of its PD-L2 expression test. The first of its kind, the new blood test enables highly sensitive and specific profiling and monitoring of PD-L2 expression in cancer cells recovered from a simple blood draw.

Cynvenio’s PD-L2 test is the first commercial RUO test that measures PD-L2 expression in circulating tumor cells (CTCs). Recent study data have shown that PD-L2 expression provides valuable information beyond PD-L1 positivity in predicting clinical response to pembrolizumab (Keytruda®) in head and neck squamous cell carcinoma (HNSCC)?.

“The PD-1 pathway is an important therapeutic target in various cancer types,” commented Paul Dempsey, Ph.D., Chief Scientific Officer at Cynvenio Biosystems. “Our new PD-L2 assay enables researchers to more fully understand another target and another regulator of immune evasion. This may contribute to determining which patients may better respond to checkpoint inhibition.”

For additional information or to order the test, please contact Cynvenio at 888-885-1172.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com, and http://www.liquidbiopsy.com.

?Yearley et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017 Jun 15;23(12):3158-3167.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14665268.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio Launches Newest LiquidBiopsy HER2 Expression Test
2. Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy
3. Cynvenio Announces New LiquidBiopsy Test for PD-L1 Expression in Lung Cancer
4. Cynvenio Announces New Deployment of LiquidBiopsy® System at Leading Cancer Research Center in South Korea
5. Cynvenio Announces ClearID® Commercial Distribution Agreements for Israel, Greece, Argentina and South Korea
6. Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois
7. Cynvenio Research Highlights Need for Longitudinal Monitoring of Triple Negative Breast Cancer Patients
8. Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
9. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
10. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
11. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring ... kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
Breaking Biology News(10 mins):